Volume 9, Issue 2 (4-2023)
Journal of Research in Applied and Basic Medical Sciences 2023, 9(2): 103-108 |
Back to browse issues page
Assistant Professor, Department of Medicine, Dharamsinh Desai University DD University Campus, Nadiad, Gujarat, India , kunjan7290@gmail.com
Abstract: (1038 Views)
Background & Aims: Coronavirus disease-2019 (COVID-19) is a newly discovered viral illness for which there is no proven cure at this time. We sought to establish the value of C-reactive protein (CRP) levels and chest X-ray morphology in determining the severity of COVID-19 disease and to correlate them with related mortality.
Materials & Methods: Data of COVID-19 patients with clinical outcomes in a small-designated hospital in Nadiad (Gujarat, India), collected retrospectively from March 15 to May 31, 2020. Patients with COVID-19 had their admission CRP's prognostic value, and chest X-ray morphology assessed.
Results: Out of 85 patients enrolled, 72 survived and 13 died. With an area under the curve (AUC) of 0.808 (95 percent CI, 0.708–0.885; P=0.001), the ROC curve analysis revealed moderate accuracy to identified mortality. Our model had an elevated CRP value of 0.105 units, which corresponded to an increased mortality rate of 1.11 times (Wald=12.73, 1.11(1.05, 1.18).
Conclusion: In contrast to the RT-PCR test, our investigation found that CRP and chest X-ray morphology were excellent predictors of earlier diagnosed COVID-19 patients. We want to require a larger sample size and to identify an additional biomarker that reduces mortality.
Materials & Methods: Data of COVID-19 patients with clinical outcomes in a small-designated hospital in Nadiad (Gujarat, India), collected retrospectively from March 15 to May 31, 2020. Patients with COVID-19 had their admission CRP's prognostic value, and chest X-ray morphology assessed.
Results: Out of 85 patients enrolled, 72 survived and 13 died. With an area under the curve (AUC) of 0.808 (95 percent CI, 0.708–0.885; P=0.001), the ROC curve analysis revealed moderate accuracy to identified mortality. Our model had an elevated CRP value of 0.105 units, which corresponded to an increased mortality rate of 1.11 times (Wald=12.73, 1.11(1.05, 1.18).
Conclusion: In contrast to the RT-PCR test, our investigation found that CRP and chest X-ray morphology were excellent predictors of earlier diagnosed COVID-19 patients. We want to require a larger sample size and to identify an additional biomarker that reduces mortality.
Type of Study: orginal article |
Subject:
Special
References
1. Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microb 2020;58(5):e00310-20. [DOI:10.1128/JCM.00310-20] [PMID] []
2. Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T, et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature 2020;584(7820):262-7. [DOI:10.1038/s41586-020-2404-8] [PMID]
3. Mas-Coma S, Jones MK, Marty AM. COVID-19 and globalization. One health 2020;9. [DOI:10.1016/j.onehlt.2020.100132] [PMID] []
4. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Ajr Am J Roentgenol 2020;215(1):87-93. [DOI:10.2214/AJR.20.23034] [PMID]
5. WHO, Coronavirus Disease (COVID-19), Situation Report, WHO, Geneva, Switzerland, 2020. [URL]
6. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020;50(4):332-4. [DOI:10.1016/j.medmal.2020.03.007] [PMID] []
7. Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, et al. Proinflammatory cytokines, aging,and age-related diseases. J Am Med Dir Assoc 2013;14:877-82. [DOI:10.1016/j.jamda.2013.05.009] [PMID]
8. Macros A, Hassanien A, Sami Atta M. Predictive value of C-reactive protein in critically ill patients who develop acute lung injury. Egypt J Chest Dis Tuberc 2014; 46: 225-36. [DOI:10.1016/j.ejcdt.2014.10.006]
9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5] [PMID]
10. Lei Y, Zhang HW, Yu J, Patlas MN. COVID-19 infection: early lessons. Can Assoc Radiol J 2020;71(3):251-2. [DOI:10.1177/0846537120914428] [PMID]
11. Zhang J, Tian S, Lou J, Chen Y. Familial cluster of COVID-19 infection from an asymptomatic. Crit Care 2020;24(1):1-3. [DOI:10.1186/s13054-020-2817-7] [PMID] []
12. Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Korean J Radiol 2020;21(4):494-500. [DOI:10.3348/kjr.2020.0132] [PMID] []
13. Damiano C, Michela P, Francesco P, Tiziano P, Carlotta R, Gisella G. Chest CT features of COVID-19 in Rome, Italy. Radiology 2020. [Google Scholar]
14. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology 2020:1-7. [DOI:10.1148/radiol.2020200463] [PMID] []
15. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infec 2020;81(1):e33-9. [DOI:10.1016/j.jinf.2020.04.004] [PMID] []
16. Wong HY, Lam HY, Fong AH, Leung ST, Chin TW, Lo CS, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2020. [Google Scholar]
17. Giovagnoni A. Facing the COVID-19 emergency: we can and we do. Radiol Med 2020;125(4):337-8. [DOI:10.1007/s11547-020-01178-y] [PMID] []
18. "ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection," American College of Radiology, 2020.
19. Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Inf Dis 2020;7(5):153. [DOI:10.1093/ofid/ofaa153] [PMID] []
20. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID‐19. J Med Virol 2020;92(7):791-6. [DOI:10.1002/jmv.25770] [PMID] []
21. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early. J Med Virol 2020;92(7):856-62. [DOI:10.1002/jmv.25871] [PMID] []
22. Mo P, Xing Y, Xiao YU, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Inf Dis 2020;73(1):e4208. [DOI:10.1093/cid/ciaa270] [PMID] []
23. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with coronavirus 2019. Clin Inf Dis 2020;71(16):2174-9. [DOI:10.1093/cid/ciaa641] [PMID] []
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |